BR112012017800B1 - composição anestésica ou sedativa - Google Patents

composição anestésica ou sedativa Download PDF

Info

Publication number
BR112012017800B1
BR112012017800B1 BR112012017800-8A BR112012017800A BR112012017800B1 BR 112012017800 B1 BR112012017800 B1 BR 112012017800B1 BR 112012017800 A BR112012017800 A BR 112012017800A BR 112012017800 B1 BR112012017800 B1 BR 112012017800B1
Authority
BR
Brazil
Prior art keywords
cyclodextrin
anesthetic
alfaxalone
neuroactive steroid
ether
Prior art date
Application number
BR112012017800-8A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112012017800A2 (en
BR112012017800A8 (pt
Inventor
Juliet Marguerite Goodchild
Colin Stanley Goodchild
Benjamin James Boyd
Original Assignee
Drawbridge Pharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drawbridge Pharmaceuticals Pty Ltd filed Critical Drawbridge Pharmaceuticals Pty Ltd
Publication of BR112012017800A2 publication Critical patent/BR112012017800A2/en
Publication of BR112012017800A8 publication Critical patent/BR112012017800A8/pt
Publication of BR112012017800B1 publication Critical patent/BR112012017800B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112012017800-8A 2010-01-21 2011-01-19 composição anestésica ou sedativa BR112012017800B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29724910P 2010-01-21 2010-01-21
US61/297,249 2010-01-21
US38531810P 2010-09-22 2010-09-22
US61/385,318 2010-09-22
PCT/AU2011/000050 WO2011088503A1 (en) 2010-01-21 2011-01-19 Anaesthetic formulation

Publications (3)

Publication Number Publication Date
BR112012017800A2 BR112012017800A2 (en) 2018-07-10
BR112012017800A8 BR112012017800A8 (pt) 2018-08-14
BR112012017800B1 true BR112012017800B1 (pt) 2020-12-08

Family

ID=44306295

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012017800-8A BR112012017800B1 (pt) 2010-01-21 2011-01-19 composição anestésica ou sedativa

Country Status (27)

Country Link
US (2) US8697678B2 (https=)
EP (1) EP2525798B1 (https=)
JP (1) JP5930311B2 (https=)
KR (1) KR101747476B1 (https=)
CN (1) CN102802635B (https=)
AU (1) AU2011207103B2 (https=)
BR (1) BR112012017800B1 (https=)
CA (1) CA2786762C (https=)
CL (1) CL2012002032A1 (https=)
CY (1) CY1119947T1 (https=)
DK (1) DK2525798T3 (https=)
ES (1) ES2646829T3 (https=)
GB (2) GB2484244B (https=)
HR (1) HRP20171699T1 (https=)
HU (1) HUE035441T2 (https=)
LT (1) LT2525798T (https=)
NO (1) NO2525798T3 (https=)
NZ (1) NZ601255A (https=)
PL (1) PL2525798T3 (https=)
PT (1) PT2525798T (https=)
RS (1) RS56576B1 (https=)
RU (1) RU2574022C2 (https=)
SG (1) SG181997A1 (https=)
SI (1) SI2525798T1 (https=)
SM (1) SMT201700518T1 (https=)
WO (1) WO2011088503A1 (https=)
ZA (1) ZA201205370B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101583620B (zh) 2005-11-28 2016-08-17 马里纳斯医药公司 加奈索酮组合物及其制备和使用方法
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
ES2784629T3 (es) * 2011-11-29 2020-09-29 Jurox Pty Ltd Composiciones farmacéuticas inyectables estables que comprenden 2-hidroxipropil-beta-ciclodextrina y alfaxalona
SG10201606063RA (en) * 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
US20140050789A1 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
MX2015002252A (es) * 2012-08-21 2015-07-21 Sage Therapeutics Inc Metodos para tratar epilepsia o estado de epilepsia.
WO2014071449A1 (en) 2012-11-09 2014-05-15 Goodchild Investments Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
DK2925327T3 (da) * 2012-11-30 2024-03-25 Univ California Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression
WO2015134670A1 (en) * 2014-03-05 2015-09-11 Mingbao Zhang Deuterated ganaxolone derivatives
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
EP4059522A1 (en) * 2015-02-06 2022-09-21 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
AR105044A1 (es) * 2015-06-18 2017-08-30 Sage Therapeutics Inc Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
EA036155B1 (ru) 2015-10-16 2020-10-06 Маринус Фармасьютикалс, Инк. Инъекционные составы нейростероида, содержащие наночастицы
HK1258616A1 (zh) 2016-03-08 2019-11-15 Sage Therapeutics, Inc. 神经活性类固醇、组合物、及其用途
EP4233861A3 (en) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
WO2019202640A1 (ja) 2018-04-16 2019-10-24 川崎重工業株式会社 ベルトコンベヤ
EP3818068B1 (en) * 2018-07-03 2025-10-29 Drawbridge Pharmaceuticals Pty Ltd Neuroactive steroids and methods of preparation
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
WO2020123551A1 (en) * 2018-12-10 2020-06-18 Halo Science LLC Stable formulations of anesthetics and associated dosage forms
CN114728012A (zh) 2019-08-05 2022-07-08 马瑞纳斯制药公司 用于治疗癫痫持续状态的加奈索酮
JP7780431B2 (ja) 2019-12-06 2025-12-04 マリナス ファーマシューティカルズ， インコーポレイテッド 結節性硬化症の治療での使用のためのガナキソロン
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
US12186327B2 (en) 2022-08-29 2025-01-07 Lipocine Inc. Oral allopregnanolone compositions and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE100712T1 (de) * 1989-05-24 1994-02-15 Innovet Inc Hypoallergene anaesthesierende/hypnotische steroide arzneizubereitung.
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1993017711A1 (en) * 1992-03-11 1993-09-16 Australian Commercial Research & Development Limited New cyclodextrins and new formulated drugs
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
JP4227675B2 (ja) * 1996-10-25 2009-02-18 康武 日地 神経毒軽減麻酔剤
AUPQ633900A0 (en) * 2000-03-20 2000-04-15 Jurox Pty Ltd Anaesthetic composition
RU2288921C2 (ru) * 2000-12-19 2006-12-10 Калифорниа Инститьют оф Текнолоджи Композиции, содержащие комплексы включения
JP4334229B2 (ja) * 2001-03-20 2009-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
IL152575A (en) 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
CN101583620B (zh) * 2005-11-28 2016-08-17 马里纳斯医药公司 加奈索酮组合物及其制备和使用方法

Also Published As

Publication number Publication date
GB2484244B (en) 2012-10-31
HRP20171699T1 (hr) 2018-01-26
US8697678B2 (en) 2014-04-15
GB2491491A (en) 2012-12-05
CN102802635B (zh) 2014-07-30
US20120316146A1 (en) 2012-12-13
NO2525798T3 (https=) 2018-01-06
BR112012017800A2 (en) 2018-07-10
PT2525798T (pt) 2017-11-15
WO2011088503A1 (en) 2011-07-28
AU2011207103B2 (en) 2013-03-21
US8975245B2 (en) 2015-03-10
NZ601255A (en) 2013-09-27
EP2525798A1 (en) 2012-11-28
CL2012002032A1 (es) 2012-12-21
LT2525798T (lt) 2018-01-10
ES2646829T3 (es) 2017-12-18
EP2525798B1 (en) 2017-08-09
HUE035441T2 (en) 2018-05-02
RU2012134321A (ru) 2014-02-27
GB201201842D0 (en) 2012-03-21
JP2013517299A (ja) 2013-05-16
CY1119947T1 (el) 2018-12-12
US20140066417A1 (en) 2014-03-06
EP2525798A4 (en) 2014-02-19
CA2786762A1 (en) 2011-07-28
KR101747476B1 (ko) 2017-06-14
PL2525798T3 (pl) 2018-05-30
SG181997A1 (en) 2012-08-30
KR20120136347A (ko) 2012-12-18
GB201210657D0 (en) 2012-08-01
SMT201700518T1 (it) 2018-01-11
HK1169031A1 (en) 2013-01-18
AU2011207103A1 (en) 2012-07-26
BR112012017800A8 (pt) 2018-08-14
SI2525798T1 (en) 2018-01-31
GB2484244A (en) 2012-04-04
RS56576B1 (sr) 2018-02-28
JP5930311B2 (ja) 2016-06-08
CN102802635A (zh) 2012-11-28
CA2786762C (en) 2017-12-05
ZA201205370B (en) 2013-09-25
DK2525798T3 (da) 2017-11-20
GB2491491B (en) 2014-07-30
RU2574022C2 (ru) 2016-01-27

Similar Documents

Publication Publication Date Title
BR112012017800B1 (pt) composição anestésica ou sedativa
BR112014012985B1 (pt) Composição farmacêutica injetável, seu método de produção e uso, bem como método de conservação de uma composição farmacêutica injetável e uso de pelo menos um co-solvente e pelo menos um conservante
KR20150050595A (ko) 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
BR112017026904B1 (pt) Formulações farmacêuticas injetáveis de lefamulina, e seu uso
US12070447B2 (en) Parenteral liquid preparation comprising carbamate compound
BR112021007987A2 (pt) formulação à base de ciclodextrina de um inibidor de bcl-2
AU2013200895B2 (en) Anaesthetic formulation
ES2657937T3 (es) Métodos y formulaciones de meclizina inyectables
AU2014200491A1 (en) Anaesthetic formulation
BR112019011914B1 (pt) Formulação líquida parenteral, composição injetável, e, método para preparar uma formulação líquida parenteral

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: DRAWBRIDGE PHARMACEUTICALS PTY LTD (AU)

B25G Requested change of headquarter approved

Owner name: DRAWBRIDGE PHARMACEUTICALS PTY LTD (AU)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/01/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2863 DE 18-11-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.